These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23927857)

  • 1. Good pharma, bad pharma.
    Drug Ther Bull; 2013 Aug; 51(8):85. PubMed ID: 23927857
    [No Abstract]   [Full Text] [Related]  

  • 2. Mixing drugs. Latest pharma deals unlikely to affect prices: experts.
    Galloro V
    Mod Healthc; 2009 Mar; 39(11):14. PubMed ID: 19415830
    [No Abstract]   [Full Text] [Related]  

  • 3. An audience with...Sir John Sulston.
    Sulston J
    Nat Rev Drug Discov; 2005 Feb; 4(2):98. PubMed ID: 15756755
    [No Abstract]   [Full Text] [Related]  

  • 4. Excluding NICE from early stages of value based pricing scheme was "big win for pharma," conference is told.
    Limb M
    BMJ; 2013 Nov; 347():f6906. PubMed ID: 24246840
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceutical industry guide. The chosen few.
    Watts G
    Health Serv J; 2002 Nov; 112(5833):suppl 10-1. PubMed ID: 12478711
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 7. New agreement on branded drugs for the NHS.
    Naci H; Dixon J
    BMJ; 2019 Jan; 364():l266. PubMed ID: 30658964
    [No Abstract]   [Full Text] [Related]  

  • 8. A multidimensional framework for specialty drug management.
    Bell GK; Baumann SA
    Manag Care; 2013 Mar; 22(3):30-5. PubMed ID: 23610804
    [No Abstract]   [Full Text] [Related]  

  • 9. Access to medicines is not the business of the pharma industry.
    Brown PJ
    J Int Assoc Physicians AIDS Care (Chic); 2002; 1(1):9-11; discussion 12-4. PubMed ID: 12942664
    [No Abstract]   [Full Text] [Related]  

  • 10. Sending pharma better signals.
    Avorn J
    Science; 2005 Jul; 309(5735):669. PubMed ID: 16051753
    [No Abstract]   [Full Text] [Related]  

  • 11. Repackaging.
    Prescrire Int; 2016 Jan; 25(167):10. PubMed ID: 26942252
    [No Abstract]   [Full Text] [Related]  

  • 12. The quiet revolution.
    Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
    [No Abstract]   [Full Text] [Related]  

  • 13. At a glance: economic impact of industry-sponsored clinical trials of pharmaceutical products.
    Varmaghani M; Heidari E; Reiner Ž; Sahebkar A
    J Med Econ; 2020 Oct; 23(10):1193-1195. PubMed ID: 32580595
    [No Abstract]   [Full Text] [Related]  

  • 14. Back on target.
    Webb S
    Nat Biotechnol; 2013 Mar; 31(3):191-3. PubMed ID: 23471062
    [No Abstract]   [Full Text] [Related]  

  • 15. The premium of a big pharma license deal.
    O'Connell KE; Frei P; Dev KK
    Nat Biotechnol; 2014 Jul; 32(7):617-9. PubMed ID: 25004224
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharma focus. Saints and sinners.
    Lewis C
    Health Serv J; 2003 Nov; 113(5883):suppl 5. PubMed ID: 14671866
    [No Abstract]   [Full Text] [Related]  

  • 17. CETA: a win for Canada or European pharma?
    Webster PC
    CMAJ; 2014 Oct; 186(15):E565-6. PubMed ID: 25267767
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharma faces major challenges after a year of failures and heated battles.
    Frantz S
    Nat Rev Drug Discov; 2007 Jan; 6(1):5-7. PubMed ID: 17269157
    [No Abstract]   [Full Text] [Related]  

  • 19. Good pharma? Bad pharma? Better pharma.
    Hardman M
    J R Coll Physicians Edinb; 2014; 44(4):269-72. PubMed ID: 25516893
    [No Abstract]   [Full Text] [Related]  

  • 20. Priced out of the UK market.
    Moran N
    Nat Biotechnol; 2008 Feb; 26(2):151-4. PubMed ID: 18259163
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.